Systemic low-dose doxycycline and alendronate administration and serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats

Journal of Periodontology

Volumn 76, Issue 11, 2005, Pages 1927-1933

  Buduneli, Eralp ^a   Buduneli, Nurcan ^a   Vardar Şengül, Saynur ^a   Kardeşler, Levent ^a   Atilla, Gül ^a   Lappin, David ^b   Kinane, Denis F ^c  

^a EGE UNIVERSITY   (Turkey)

^b GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alendronate; Alveolar bone loss; C reactive protein; Doxycycline; Interleukin 1 ; Osteocalcin

Indexed keywords

ALENDRONIC ACID; C REACTIVE PROTEIN; DOXYCYCLINE; ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; OSTEOCALCIN; SODIUM CHLORIDE;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BONE REMODELING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PERIODONTITIS; PROTEIN BLOOD LEVEL; RAT; STATISTICAL SIGNIFICANCE;

ALENDRONATE; ALVEOLAR BONE LOSS; ANIMALS; ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; C-REACTIVE PROTEIN; DOXYCYCLINE; ENDOTOXINS; ESCHERICHIA COLI; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; OSTEOCALCIN; PERIODONTITIS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE;

EID: 28644432638     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.11.1927     Document Type: Article

References (36)

1. 2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44:1165-1170.
2. 2. J Rheumatol 1998;25:1807-1812.
3. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planning in patients with adult periodontitis. J Periodontol 2000;71:521-532.
4. Buduneli E, Vardar S, Buduneli N, et al. Effects of combined systemic administration of doxycycline and alendronate on endotoxin-induced periodontitis in rats. J Periodontol 2004;75:1516-1523.
5. Sato M, Grasser W. Effects of biphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
6. Alencar VB, Bezerra MM, Lima V, et al. Disodium clodronate prevents bone resorption in experimental periodontitis in rats. J Periodontol 2002;73:251-256.
7. Mitsuta T, Horiuchi H, Shinoda H. Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. J Periodontol 2002;73:479-486.
8. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88: 2095-2105.
9. Tenenbaum HC, Shelemany A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73:813-822.
10. El-Shinnawi UM, El-Tantawi SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5:5-10.
11. Lian JB, Gundberg CM. Osteocalcin: Biochemical considerations and clinical applications. Clin Orthop Relat Res 1988;226:267-291.
12. Christenson RH. Biochemical markers of bone metabolism: An overview. Clin Biochem 1997;30:573-593.
13. Shi F, Yu S, Xu L. Analysis of serum osteocalcin of patients with periodontitis (in Chinese). Zhonghua Kou Qiang Yi Xue Za Zhi 1996;31:300-302.
14. Ebersole JL, Capelli D. Acute-phase reactants in infections and inflammatory diseases. Periodontol 2000 2000;23:19-49.
15. Ebersole JL, Machen RL, Steffen MJ, Willmann DE. Systemic acute-phase reactants, C-reactive protein and haptoglobulin, an adult periodontitis. Clin Exp Immunol 1997;107:347-352.
16. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 2000;71: 1528-1534.
17. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease. Arch Intern Med 2000;160:2749-2755.
18. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001;72:1221-1227.
19. Rocha ML, Malacara JM, Sanchez-Marin FJ, Vasquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopousal women: A randomized placebo-controlled trial. J Periodontol 2004;75:1579-1585.
20. Ramamurthy NS, Golub LM, Gwinnett AJ, Salo T, Ding Y, Sorsa T. In vivo and in vitro inhibition of metalloproteinases including MMP-13 by several chemically modified tetracyclines (CMTs). In: Davidovitch D, Mah J, eds. Biologic Mechanisms of Tooth Eruption, Resorption and Replacement by Implants. Boston: Harvard Society for the Advancement of Orthodontics; 1998:271-277.
21. Yaffe A, Fine N, Alt I, Binderman I. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 1995;66:999-1003.
22. Sugawara S, Shibazaki M, Takada H, Kosugi H, Endo Y. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor alpha in mice. Br J Pharmacol 1998;125:735-740.
23. Ide M, McPartlin D, Coward PY, Crook M, Lumb P, Wilson RF. Effect of treatment of chronic periodontitis on levels of serum markers of acute-phase inflammatory and vascular responses. J Clin Periodontol 2003; 30:334-340.
24. Ide M, Jagdev D, Coward PY, Crook M, Barclay GR, Wilson RF. The short-term effects of treatment of chronic periodontitis on circulating levels of endotoxin, C-reactive protein, tumor necrosis factor-α, and interleukin-6. J Periodontol 2004;75:420-428.
25. Ylikorkala O, Eviö S, Valimaki M, Tiitinen A. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 2003;80:541-545.
26. Kunimatsu K, Mataki S, Tanaka H, et al. A cross-sectional study on osteocalcin levels in gingival crevicular fluid from periodontal patients. J Periodontol 1993;64:865-869.
27. 2 and alkaline phosphatase in gingival crevicular fluid: Their relations to periodontal status. J Clin Periodontol 1994;21:327-333.
28. Lee AJ, Walsh TF, Hodges SJ, Rawlinson A. Gingival crevicular fluid osteocalcin in adult periodontitis. J Clin Periodontol 1999;26:252-256.
29. Murata M, Tatsumi J, Kato Y, et al. Osteocalcin, deoxypyridinoline and interleukin-1beta in peri-implant crevicular fluid of patients with peri-implantitis. Clin Oral Implants Res 2002;13:637-643.
30. Koyama N, Ohara K, Yokota H, et al. A one step sandwich enzyme immunoassay for γ-carboxylated osteocalcin using monoclonal antibodies. J Immunol Methods 1991;139:17-23.
31. Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 1995;30:277-284.
32. Rocha M, Nava LE, de la Torre CV, Sanchez-Marin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;72:204-209.
33. Shibutani T, Inuduka A, Horiki I, Luan Q, Iwayama Y. Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs. Clin Oral Implants Res 2001;12:109-114.
34. Llavaneras A, Ramamurthy NS, Heikkila P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats. J Periodontol 2001;72:1069-1077.
35. Yaffe A, Herman A, Bahar H, Binderman I. Combined local application of tetracycline and reduces alveolar bone resorption in rats. J Periodontol 2003;74:1038-1042.
36. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997;46:310-319.